{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:34:17Z","timestamp":1791250457602,"version":"4.1.0"},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,4,4]],"date-time":"2012-04-04T00:00:00Z","timestamp":1333497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There are two different international standards for the treatment of follicular lymphoma (FL): intensified therapy followed by autologous stem\u2010cell transplantation (ASCT) and conventional therapy in the first\u2010line setting. However, their role remains unclear. Our aim was to define the treatment effect of intensified therapy followed by ASCT compared with conventional therapy as first\u2010line treatment of patients with FL in terms of overall survival (OS) and event\u2010free survival (EFS). We searched for randomised controlled trials in Medline, Embase, the Cochrane controlled trials register and the Science Citation Index (1985 to June 2011). Effect measures used were hazard ratios (HR) for OS, EFS and secondary tumour rate. Two independent review authors extracted data and assessed quality of trials. Four trials were identified, covering a total of 941 subjects. The random\u2010effects summary HR by comparing the treatment effect on OS between intensified and conventional therapy was 0.95 [0.70, 1.30] (<jats:italic>p<\/jats:italic>\u2009=\u20090.75), indicating that no additional survival benefit was derived from the intensified therapy followed by ASCT. A significant benefit of intensified therapy followed by ASCT as first\u2010line treatment was detected in terms of EFS: the random\u2010effects summary HR (intensified versus conventional therapy) was 0.59 [0.44, 0.79] (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). This meta\u2010analysis showed that despite its superior EFS, intensified therapy followed by ASCT does not improve the OS compared with conventional therapy. Copyright \u00a9 2012 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.2015","type":"journal-article","created":{"date-parts":[[2012,4,5]],"date-time":"2012-04-05T04:17:24Z","timestamp":1333599444000},"page":"29-33","source":"Crossref","is-referenced-by-count":12,"title":["Intensified therapy followed by autologous stem\u2010cell transplantation (ASCT) versus conventional therapy as first\u2010line treatment of follicular lymphoma: a meta\u2010analysis"],"prefix":"10.1002","volume":"31","author":[{"given":"Baohong","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology Weifang People's Hospital  Shandong Weifang 261041 China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiai","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Hematology Weifang People's Hospital  Shandong Weifang 261041 China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weide","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shouguang Mental Health Center  Shandong Weifang 261041 China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ma","sequence":"additional","affiliation":[{"name":"ICU Weifang People's Hospital  Shandong Weifang 261041 China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingsen","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Hematology Weifang People's Hospital  Shandong Weifang 261041 China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixin","family":"Sheng","sequence":"additional","affiliation":[{"name":"Department of Hematology Weifang People's Hospital  Shandong Weifang 261041 China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,4,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2780"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2004.06.034"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704654"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.019"},{"key":"e_1_2_7_6_1","first-page":"811","article-title":"Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re\u2010treatment and maintenance","volume":"88","author":"Cohen Y","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008399623564"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199111283252201"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3920"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116749"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0982"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-013193"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-160200"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780080202"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.2307\/2533446"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.023"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.8327"},{"key":"e_1_2_7_22_1","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood.V100.4.1141.h81602001141_1141_1152","article-title":"Intensive therapies in follicular non\u2010Hodgkin lymphomas","volume":"100","author":"Hunault\u2010Berger M","year":"2002","journal-title":"Blood"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(01)00159-7"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2015","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T04:53:10Z","timestamp":1700628790000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,4]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1002\/hon.2015"],"URL":"https:\/\/doi.org\/10.1002\/hon.2015","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,4]]}}}